Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis
The gut microbiota is involved in the development of the immune system and can modulate the risk for immune-mediated disorders such as multiple sclerosis (MS). Dysbiosis has been demonstrated in MS patients and its restoration by disease-modifying treatments (DMTs) is hypothesized. We aimed to study...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2720 |
| Summary: | The gut microbiota is involved in the development of the immune system and can modulate the risk for immune-mediated disorders such as multiple sclerosis (MS). Dysbiosis has been demonstrated in MS patients and its restoration by disease-modifying treatments (DMTs) is hypothesized. We aimed to study the changes in gut microbiota composition during the first 6 months of treatment with dimethyl fumarate (DMF), an oral DMT, and to identify the microorganisms associated with DMF side effects. We collected and analyzed the gut microbiota of 19 MS patients at baseline and after 1, 3, and 6 months of DMF treatment. We then cross-sectionally compared gut microbiota composition according to the presence of gastrointestinal (GI) symptoms and flushing. Overall, the gut microbiota biodiversity showed no changes over the 6-month follow-up. At the genus level, DMF was associated with decreased <i>Clostridium</i> abundance after 6 months. In subjects reporting side effects, a higher abundance of <i>Streptococcus</i>, <i>Haemophilus</i>, <i>Clostridium</i>, <i>Lachnospira</i>, <i>Blautia</i>, <i>Subdoligranulum</i>, and Tenericutes and lower of <i>Bacteroidetes</i>, <i>Barnesiella</i>, <i>Odoribacter</i>, <i>Akkermansia</i>, and some Proteobacteria families were detected. Our results suggest that gut microbiota may be involved in therapeutic action and side effects of DMF, representing a potential target for improving disease course and DMT tolerability. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |